PMID- 15563742
OWN - NLM
STAT- MEDLINE
DCOM- 20050503
LR  - 20131121
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 20 Suppl 2
DP  - 2004
TI  - Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: 
      results of a pilot 2-week, open-label study using the Neuropathic Pain Scale.
PG  - S13-9
AB  - OBJECTIVE: To determine the impact of the lidocaine patch 5% on distinct pain 
      qualities associated with osteoarthritis (OA) through use of the Neuropathic Pain 
      Scale (NPS), an assessment tool designed to assess intensity of various pain 
      qualities (i.e.sharp, dull). PATIENTS AND METHODS: Patients were enrolled in a 
      prospective, open-label, non-randomized, parallel-group, 2-week study involving 8 
      clinical trial sites in the United States. Eligible patients had radiographic 
      evidence of OA involving one or both knees and reported moderate-to-severe pain 
      (despite prn or stable doses of analgesics) on the NPS at study enrollment. 
      Patients on prn analgesics were discontinued from all analgesic regimens prior to 
      study entry and received lidocaine patch 5% as monotherapy. Those on stable doses 
      of analgesics were continued on their other analgesic regimens with no additions 
      or dose alterations allowed other than the lidocaine patch 5% as add-on therapy. 
      The lidocaine patch 5% was applied to the area of maximal pain, using no more 
      than a total of 4 patches changed every 24 h. Effectiveness was measured by 
      change from baseline to Week 2 in 4 composite measures of the NPS: NPS-10, NPS-4, 
      NPS-8, and NPS-nonallodynia. Safety was assessed by adverse events (AEs), dermal 
      assessment of application site(s), and skin sensory testing. RESULTS: In the 
      combined patient population (n = 100), 2 weeks of treatment with lidocaine patch 
      5% significantly improved all 4 NPS composite measures (p < 0.001). Separate 
      analyses by subgroups revealed significant improvements in all 4 composite 
      measures for both the monotherapy group (n = 12; p < 0.01) and add-on therapy 
      group (n = 88; p < 0.001). No treatment-related AEs were reported for the 
      monotherapy group. In the add-on therapy group, 5 patients experienced 
      mild-to-moderate treatment-related AEs. CONCLUSIONS: In patients with 
      moderate-to-severe OA of the knee, 2 weeks of treatment with the lidocaine patch 
      5% significantly reduces the intensity of pain qualities as measured by all 4 NPS 
      composite measures. Our results coincide with previously reported improvements in 
      pain and physical function in the same patient population, as measured by the 
      Western Ontario and McMaster Universities OA Index. Measuring the various 
      qualities of pain appears to be a valid approach for assessing clinical outcomes 
      in the treatment of OA pain. Pain measures such as the NPS can capture the 
      multi-dimensional properties of a patient's pain experience and may offer 
      clinicians the possibility to identify differential effects of analgesic 
      treatments on various pain qualities associated with OA.
FAU - Gammaitoni, Arnold R
AU  - Gammaitoni AR
AD  - Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA. Gammaitoni.Arnold@Endo.com
FAU - Galer, Bradley S
AU  - Galer BS
FAU - Onawola, Roland
AU  - Onawola R
FAU - Jensen, Mark P
AU  - Jensen MP
FAU - Argoff, Charles E
AU  - Argoff CE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anesthetics, Local)
RN  - 98PI200987 (Lidocaine)
SB  - IM
MH  - Administration, Cutaneous
MH  - Anesthetics, Local/*administration & dosage
MH  - Female
MH  - Humans
MH  - Lidocaine/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis, Knee/*complications
MH  - Pain/*drug therapy/etiology
MH  - Pain Measurement/*methods
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - United States
EDAT- 2004/11/27 09:00
MHDA- 2005/05/04 09:00
CRDT- 2004/11/27 09:00
PHST- 2004/11/27 09:00 [pubmed]
PHST- 2005/05/04 09:00 [medline]
PHST- 2004/11/27 09:00 [entrez]
AID - 10.1185/030079904X12951 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2004;20 Suppl 2:S13-9. doi: 10.1185/030079904X12951.